Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Fig. 1

Therapeutic efficacy of antibody cocktail composed of the sMIC-targeting antibody B10G5 and an anti-PD-L1 antibody in the autochthonous bi-transgenic TRAMP/MICB mice. a, Depiction of the therapy schema. Cohorts of 27 to 29-week-old TRAMP/MICB mice (male) were assigned to four therapy groups according to similar distribution of serum levels of sMIC for the four defined therapy. All therapies were given twice weekly for 8 weeks. b, Prostate organ weight, which reflects tumor weight in situ, of the animals at necropsy after receiving an 8-week duration of specific therapy. c, Incidence of lung metastasis in animals of each therapeutic group after a duration of 8-week therapy. Due to multiple focal micrometastasis in distant organs, quantitation of micrometastasis in each organ is not achievable. d, Kaplan-Meier survival at the designated study point (end of 8-week therapy). ns, not statistically significant

Back to article page